Health
Anti-SARS-CoV-2 drug candidate enters phase I clinical trial – News-Medical.Net
DC402234 (FB2001), an anti-SARS-CoV-2 drug candidate mainly developed by research team at the Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of…
DC402234 (FB2001), an anti-SARS-CoV-2 drug candidate mainly developed by research team at the Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences enters its Phase I clinical trial in the United States on March 15.
DC402234, a peptidomimetic compound, was designed and synthesized through analyzing the crystal structure of the coronaviruses Mpro.
Researchers found that DC402234 exhibits effective inhibitory activity against SARS-CoV-2 Mpro with IC50 values of 0.053 ± 0.005 μM,…
-
Noosa News16 hours agoTeenager sentenced to 12 years for ‘heinous’ Acacia Ridge murder
-
Noosa News14 hours agoGirl’s death in a Queensland cult
-
General14 hours agoTeen driver on cocaine racing to Perth nightclub before high-speed crash that killed Nick Campo, court hears
-
Noosa News14 hours agoAirbnb owner hit with disturbing email after house trashed by hundreds of teens